These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 1528326)
1. Collateral resistance or sensitivity of human larynx carcinoma HEp2 cells resistant to cis-dichlorodiammineplatinum (II) or vincristine sulfate. Osmak M Neoplasma; 1992; 39(3):197-202. PubMed ID: 1528326 [TBL] [Abstract][Full Text] [Related]
2. Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): cross-resistance patterns. Beketić-Oresković L; Osmak M Neoplasma; 1994; 41(3):171-6. PubMed ID: 7935986 [TBL] [Abstract][Full Text] [Related]
3. Multifactorial molecular mechanisms are involved in resistance of preirradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine. Osmak M Neoplasma; 1993; 40(2):97-101. PubMed ID: 8102478 [TBL] [Abstract][Full Text] [Related]
4. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs. Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318 [TBL] [Abstract][Full Text] [Related]
5. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. de la Torre M; Hao XY; Larsson R; Nygren P; Tsuruo T; Mannervik B; Bergh J Anticancer Res; 1993; 13(5A):1425-30. PubMed ID: 7902062 [TBL] [Abstract][Full Text] [Related]
6. Hyperthermic modulation of resistance to cis-diamminedichloroplatinum (II) in human larynx carcinoma cells. Beketić-Oresković L; Jaksić M; Oresković S; Osmak M Int J Hyperthermia; 1997; 13(2):205-14. PubMed ID: 9147146 [TBL] [Abstract][Full Text] [Related]
7. Resistance of human larynx carcinoma cells to cisplatin, gamma-irradiation and methotrexate does not involve overexpression of c-myc or c-Ki-ras oncogenes. Osmak M; Beketić-Oresković L; Matulić M; Sorić J Mutat Res; 1993 Nov; 303(3):113-20. PubMed ID: 7694127 [TBL] [Abstract][Full Text] [Related]
8. Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): mechanisms involved in the resistance. Beketić-Oresković L; Osmak M; Jaksić M Neoplasma; 1994; 41(3):163-9. PubMed ID: 7935985 [TBL] [Abstract][Full Text] [Related]
9. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes]. Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984 [TBL] [Abstract][Full Text] [Related]
10. Drug resistance and cross-sensitivity in cultured human osteosarcoma cells. Tomita K; Kontani T; Tsuchiya H; Nomura S Nihon Seikeigeka Gakkai Zasshi; 1989 Apr; 63(4):274-81. PubMed ID: 2738428 [TBL] [Abstract][Full Text] [Related]
11. Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II). Rosowsky A; Wright JE; Cucchi CA; Flatow JL; Trites DH; Teicher BA; Frei E Cancer Res; 1987 Nov; 47(22):5913-8. PubMed ID: 3664492 [TBL] [Abstract][Full Text] [Related]
12. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096 [TBL] [Abstract][Full Text] [Related]
13. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells. Fram RJ; Woda BA; Wilson JM; Robichaud N Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559 [TBL] [Abstract][Full Text] [Related]
14. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962 [TBL] [Abstract][Full Text] [Related]
15. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504 [TBL] [Abstract][Full Text] [Related]
16. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin. Chen G; Zeller WJ; Todorov DK Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496 [TBL] [Abstract][Full Text] [Related]
17. Induction of in vitro resistance to 4'-epidoxorubicin and cis-dichlorodiammineplatinum in hepatoma cells. Hall KS; Endresen L; Huitfeldt HS; Rugstad HE Anticancer Res; 1991; 11(2):817-23. PubMed ID: 1676581 [TBL] [Abstract][Full Text] [Related]
18. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547 [TBL] [Abstract][Full Text] [Related]
19. Acquired vs innate multidrug resistance and the effect of calcium channel blockers. Tsuruo T Prog Clin Biol Res; 1986; 223():203-16. PubMed ID: 3468516 [TBL] [Abstract][Full Text] [Related]
20. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. Naredi P; Heath DD; Enns RE; Howell SB Cancer Res; 1994 Dec; 54(24):6464-8. PubMed ID: 7987844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]